| Fund ID | 805-5181301611 |
| Fund type | Venture Capital Fund |
| 3(c)(1) exclusion | Yes |
| 3(c)(7) exclusion | No |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| Sales limited to qualified investors | Yes |
| % of assets independently valued | 0% |
| Owned by the adviser or related persons | 72% |
| Owned by funds of funds | 0% |
| Owned by non-U.S. persons | 4% |
| Fund | Type | Gross assets |
|---|---|---|
| Oncology Impact Fund 2, L.P. | Other Private | $1.01B |
| UBS Oncology Impact Fund L.P. | Other Private | $629.7M |
| Mpm Bioventures 2018, L.P. | Venture Capital | $548.7M |
Mpm Asset Management Investors Bv2018 LLC reports $11.6 million in gross assets, among the top 75% of private funds by size.
The stated minimum investment is $38,000.
Mpm Asset Management Investors Bv2018 LLC is managed by Mpm Asset Management LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.